- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05114369
Does Timing of Completion Radical Cholecystectomy Determine the Survival in Incidental Carcinoma Gallbladder (IGBC)
November 5, 2021 updated by: Sanjay Gandhi Postgraduate Institute of Medical Sciences
Does Timing of Completion Radical Cholecystectomy Determine the Survival Outcome in Incidental Carcinoma Gallbladder - a Single Center Retrospective Analysis
Various factors determine the long term survival in this non-uniform cohort of incidental gallbladder cancer.
Timing of re-intervention is suggested to play an important role in the outcome.
Few centers are proponents of early surgery in order to prevent dissemination, while others have suggested an intentional delay of 3 months to filter out cases with aggressive pathology.
In the present study, investigators intend to evaluate the factors affecting survival in incidental Gallbladder Cancer (IGBC) with special reference to timing of re-intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Surgical Gastroenterology department at our institute is a tertiary referral center for hepatobiliary malignancies; covering a large part of North and North-east India.
The details and progress reports of patients of Gallbladder Cancer (GBC) being referred to and treated at the institute is maintained in a prospective manner on hospital data base.
This includes demographic data, presenting complains, details of relevant investigations done outside and in the hospital, previous surgery, pre-hospital course, operative findings, post operative course and final histopathology.
Being a retrospective analysis of data not affecting clinical outcomes, ethical approval was not taken.
During the study period (Jan 2009 to Dec 2018), 1049 participants with diagnosis of GBC (including 91 IGBC participants) were admitted; 239/958 participants with diagnosis of GBC and 48/91 with diagnosis of GBC could undergo resection with curative intent.
Information regarding adjuvant therapy, recurrence, and survival were retrieved through data maintained on follow up out-patient cards till December 2019.
Few participants who stopped visiting the hospital were contacted telephonically or through letters.
All available histopathology blocks and slides following the index cholecystectomy were re-reviewed by the pathologists in the institute.
Tumor type, differentiation and primary T stage were documented for majority of cases.
Interval between index cholecystectomy and date of re-operation was calculated for all the participants and divided into 3 groups: Early (<4weeks), Intermediate (4-12 weeks) and Late (>12 weeks).
Primary objective was to assess the effect of tumor characteristics and the time gap (between index surgery and re-resection) on overall survival following curative (R0/R1) resection.
Study Type
Observational
Enrollment (Actual)
48
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All incidental carcinoma gallbladder patients who were admitted for possible curative resection during the study period (Jan 2009 to Dec 2018)
Description
Inclusion Criteria:
All incidental carcinoma gallbladder patients who could undergo curative resection during the study period (Jan 2009 to Dec 2018)
Exclusion Criteria:
Metastasis on preoperative investigation or on staging laparoscopy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Early (<4weeks), Intermediate (4-12 weeks) and Late (>12 weeks)
Interval between index cholecystectomy and radical re-resection with curative intent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival based on timing of completion radical cholecystectomy
Time Frame: 01.01.2009 to 31.12.2018
|
Overall and disease free survival
|
01.01.2009 to 31.12.2018
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determinants of factors associated with survival in incidental gallbladder carcinoma
Time Frame: 01.01.2009 to 31.12.2018
|
Factors related to primary surgery (residual disease, primary T stage), type of resection (Wedge resection, Segment 4B-5 excision or Common bile duct excision), tumor characteristics (differentiation and lymohovascular invasion) and final stage (AJCC 8th edition)
|
01.01.2009 to 31.12.2018
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2009
Primary Completion (Actual)
December 31, 2018
Study Completion (Actual)
October 1, 2021
Study Registration Dates
First Submitted
October 11, 2021
First Submitted That Met QC Criteria
November 5, 2021
First Posted (Actual)
November 10, 2021
Study Record Updates
Last Update Posted (Actual)
November 10, 2021
Last Update Submitted That Met QC Criteria
November 5, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The final data sheet can be shared and not the individual data as the data was retrieved from online database
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Survival
-
Peking University First HospitalCompletedOverall SurvivalChina
-
Columbia UniversityBill and Melinda Gates Foundation; United NationsCompletedChild SurvivalEthiopia, Ghana, Kenya, Malawi, Mali, Nigeria, Rwanda, Senegal, Tanzania, Uganda
-
University of SienaCompletedRestoration Survival
-
Metabolic Technologies Inc.Koach Sport and NutritionCompletedSurvival TrainingIsrael
-
ChimerixTerminated
-
Universitair Ziekenhuis BrusselCompletedSurvival | Embryo QualityBelgium
-
Technical University of MunichUnknown
-
Shanghai Jiao Tong University School of MedicineRecruiting
-
University Medical Center GroningenCompletedSurvival | Immediate Dentin Sealing
-
Peking Union Medical College HospitalOrigiMedRecruitingQuality of Life | Objective Response Rate | Overall Survival | Progression-free Survival | Disease Control Rate | Duration of Response | Five-year Survival RateChina
Clinical Trials on Curative surgery
-
National Taiwan University HospitalCompletedPET-driven Surgery | Loco-regional Recurrent Colorectal CancerTaiwan
-
The Catholic University of KoreaNot yet recruitingColon Cancer, Obstruction
-
South Valley UniversityRecruiting
-
The Clatterbridge Cancer Centre NHS Foundation...Bristol-Myers Squibb; University of LiverpoolActive, not recruitingSquamous Cell Carcinoma of the Oral CavityUnited Kingdom
-
National Cancer Center, KoreaRecruitingColorectal CancerKorea, Republic of
-
University of AlexandriaCompletedColorectal Cancer | Oncologic Complications and Emergencies
-
European Institute of OncologyRecruitingHPV-Related CarcinomaItaly
-
Belfast Health and Social Care TrustQueen's University, BelfastRecruitingHead and Neck Cancer | Periodontal Diseases | Radiotherapy Side Effect | Caries, DentalUnited Kingdom
-
Southwest Hospital, ChinaUnknownHepatocellular CarcinomaChina
-
Southwest Hospital, ChinaFudan University; Chinese PLA General Hospital; First Affiliated Hospital, Sun... and other collaboratorsCompletedHepatocellular CarcinomaChina